20 Best Performing Stocks in 2025

Page 17 of 18

2. Celcuity Inc. (NASDAQ:CELC)

Total Returns in 2025: 661.9%  

Number of Hedge Fund Holders: 31            

Celcuity Inc. (NASDAQ:CELC) is among the Best Performing Stocks.

On December 12, 2025, TheFly reported that Wells Fargo started covering Celcuity Inc. (NASDAQ:CELC) with a $126 price target and an Overweight rating. According to the firm, Phase 1 data and results from the wild-type cohort have significantly reduced the risk associated with the impending VIKTORIA-1 PIK3CA mutant readout. Wells Fargo also stated that the current share price is not reflecting gedatolisib’s market potential in breast cancer. Metastatic castration-resistant prostate cancer is an additional upside alternative.

Separately, as it moves forward with accelerated launch preparations, Celcuity Inc. (NASDAQ:CELC) reported peak revenue potential for gedatolisib of $2.5 billion to $3 billion in the most recent quarter. The firm noted the release of top-line data from the PIK3CA wild-type group of the Phase III VIKTORIA-1 study and discussed progress on clinical and regulatory objectives.

The PIK3CA mutant cohort wrapped up enrolling, and results are anticipated in late Q1 or Q2 2026. The company’s NDA submission under the real-time oncology review program was approved by the FDA, and it is anticipated to be finished this quarter.

The median progression-free survival for the gedatolisib triplet was 9.3 months, compared to 2 months for fulvestrant, with a hazard ratio of 0.24, as reported by Celcuity Inc. (NASDAQ:CELC). The corporation had over $455 million in cash, cash equivalents, and short-term investments at the end of the quarter, despite reporting a $43.8 million net loss.

Celcuity Inc. (NASDAQ:CELC) is a biotechnology business in the clinical stage that is working on oncology development.

Page 17 of 18